Sandoz Group (SDZ.SW, SIX) pre-market CHF67.04 21 Feb 2026 earnings: margins

SDZ.SW stock trades at CHF67.04 pre-market on 21 Feb 2026 as investors position ahead of Sandoz Group AG’s quarterly results due 25 Feb 2026. We expect the report to focus on margin recovery and biosimilars mix after the company showed strong year-to-date gains of 17.16%. Volume is tracking at 708,784 shares against an average of 736,047, so price moves may accelerate on guidance or margin detail. Meyka AI provides this earnings spotlight as an AI-powered market analysis platform to highlight the metrics that matter before the print.

Earnings setup and near-term catalysts

Sandoz Group AG reports earnings on 25 Feb 2026; SDZ.SW stock will react to gross margin, biosimilars sales and management guidance. The company lists earnings announcement time as 16:30:00 UTC+00:00 on 25 Feb 2026 and EPS trailing figure is 0.40, with a current PE of 167.60.

Expectation: watch for operating margin trends and any commentary on biosimilar uptake and anti-infective volumes. A modest revenue slowdown in 2024 (revenue growth -8.60%) raises the bar for management to show margin improvement.

Price action and technicals for SDZ.SW stock

Pre-market price is CHF67.04, near the year high CHF67.98, and above the 50-day average CHF60.37 and 200-day average CHF50.81, which supports a bullish trend. Momentum indicators show RSI 69.15 and ADX 34.57, signalling strong trend momentum but nearing overbought.

Traders should note ATR 1.62 and Bollinger top 68.34; intraday swings of ±CHF1.50 are possible if guidance surprises. On-chain flow shows on-balance volume supportive of the move with OBV 10,670,415.

Fundamentals and valuation snapshot

Sandoz Group AG operates in Healthcare (Drug Manufacturers – Specialty & Generic) with market cap CHF28,874,239,286.00 and shares outstanding 430,701,660.00. Key ratios: price/earnings 167.60, price/sales 3.99, price/book 4.24, and free cash flow per share 0.73.

The balance sheet shows debt-to-equity 0.65 and interest coverage 4.71, while net debt to EBITDA is elevated at 5.91, flagging leverage risk if cash generation weakens. These metrics explain the premium valuation despite muted net margins (net margin 2.43%).

Meyka AI grade and SDZ.SW stock forecast

Meyka AI rates SDZ.SW with a score of 68.66 out of 100, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month target of CHF81.59, implying an upside of 21.70% versus the current CHF67.04. Forecasts are model-based projections and not guarantees. We contrast the model view with a conservative near-term scenario of CHF55.00 if margins disappoint.

Sector context and analyst focus

Healthcare sector momentum is positive (3-month +10.78%), and SDZ.SW stock sits in the drug manufacturers specialty & generic segment where peers trade at a median PE below Sandoz’s. Investors will compare Sandoz margins and biosimilar growth to larger peers such as Novartis and Roche.

Analysts will emphasise guidance and cash conversion. Given long days-of-inventory (225.58) and receivables (105.46 days), working capital swings could materially affect free cash flow in the quarter.

Risks, what to watch in the print

Key downside triggers: weak biosimilars uptake, a negative margin surprise, or operational guidance cut tied to inventories and gross-to-net pressures. High valuation (PE 167.60) leaves limited room for disappointment.

Key datapoints to watch in the release: revenue growth, gross margin, operating cash flow, full-year guidance, and any comments on capex or M&A. Also monitor peer commentary from Roche and Novartis for industry-level signals source.

Final Thoughts

Key takeaways on SDZ.SW stock heading into Sandoz Group AG’s earnings: the pre-market price CHF67.04 positions the stock close to its year high, but valuation is stretched with a trailing PE of 167.60 and modest net margin 2.43%. We expect the market to reward margin improvement, clearer biosimilars volume growth, and stronger free cash flow conversion. Meyka AI’s forecast model projects a 12-month target of CHF81.59, an implied upside of 21.70% versus the current price. That upside assumes a rebound in operating margin and stable working capital. Conversely, a guidance cut or negative cash flow swing could quickly push the share price toward a conservative downside scenario near CHF55.00. Investors should treat the Meyka AI forecast and grade as model-based insights, not guarantees, and monitor the earnings release on 25 Feb 2026 and company website for official detail source. For a quick stock snapshot use our Meyka page: https://meyka.ai/stocks/SDZ.SW.

FAQs

When does Sandoz report earnings and how does that affect SDZ.SW stock?

Sandoz reports earnings on 25 Feb 2026; SDZ.SW stock typically moves on margin commentary, biosimilars sales and guidance. Expect higher volatility and volume; watch gross margin and operating cash flow for the clearest signals.

What are the main valuation metrics for SDZ.SW stock?

Key metrics: price CHF67.04, EPS 0.40, PE 167.60, P/S 3.99, P/B 4.24, and market cap CHF28,874,239,286.00. The high PE reflects low current earnings versus market expectations.

What does Meyka AI forecast for SDZ.SW stock?

Meyka AI’s forecast model projects a 12-month target of CHF81.59 for SDZ.SW stock, implying upside 21.70% from CHF67.04. Forecasts are model-based projections and not guarantees.

Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.